Methylation

• FC 12-01 • Inter-laboratory agreement of the FAM19A4/miR 124-2 methylation test - a valid-screen (H2020) sub-study See abstract > A. Arno FLOORE • FC 12-02 • The Scottish HPV archive - a resource for basic and translational research See abstract > K. Kate Cuschieri • FC 12-03 • Methylation biomarkers to triage HPV positive surepath collected screening samples See abstract > J. Jesper BONDE • FC 12-04 • Methylation pattern switch between low and high grade cervical intraepithelial neoplasia: implications for progression models, robust triage and cancer risk See abstract > M. M. KLEEMAN • FC 12-05 • Diagnostic value of methylation markers in cervical cancer screening See abstract > G. G.B. WISMAN • FC 12-06 • FAM19A4/MIR 124-2 methylation analysis for cervical cancer screening in women living with HIV See abstract > W. Wieke KREMER • FC 12-07 • HPV DNA methylation as a biomarker for improving risk stratification and clinical management of HPV-positive women See abstract > M. M. CLARKE • FC 12-08 • Clinical validation of POU4F3 methylation as a new biomarker of cervical precancer and cancer in a triage of hrHPV positive women See abstract > M. M. BENCZIK • FC 12-09 • Associations of EPB41L3 DNA methylation with cervical intraepithelial neoplasia in women living with HIV-1 in Burkina Faso and South Africa See abstract > H. H. KELLY • FC 12-10 • Cervical cancer detection by DNA methylation analysis in urine See abstract > N. N. VAN TROMMEL • FC 12-11 • Gyntect®, a DNA methylation marker panel-based diagnostic test shows very high specificity in the triage of cervical cancer screening samples See abstract > M. M. SCHMITZ • FC 12-12 • Beta-globin cycle threshold value as a predictor of sufficient DNA yield for HPV methylation analysis See abstract > A. A. OSTRBENK • FC 12-13 • Longitudinal performance of HPV 16 methylation predicting cervical precancer and cancer: a 10-year cohort study in China See abstract > L. L. ZHANG • FC 12-14 • Development of a new highly accurate DNA methylation classifier for prevalent and incident cervical precancer See abstract > B. B. NEDJAI • FC 12-15 • Risk allelic load in TH2 and TH3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study See abstract > K. K. TORRES-POVEDA